Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups
: Drug use related deaths are increasing and the lack of effective treatment for psychostimulants can be largely held responsible. Particularly, no pharmacotherapy is approved for methamphetamine (METH) use disorder despite decades of research. Only psychosocial interventions are clinically used, wi...
Saved in:
Published in | Expert opinion on pharmacotherapy Vol. 20; no. 18; p. 2273 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
12.12.2019
|
Subjects | |
Online Access | Get more information |
ISSN | 1744-7666 |
DOI | 10.1080/14656566.2019.1681970 |
Cover
Abstract | : Drug use related deaths are increasing and the lack of effective treatment for psychostimulants can be largely held responsible. Particularly, no pharmacotherapy is approved for methamphetamine (METH) use disorder despite decades of research. Only psychosocial interventions are clinically used, with limited long-term recovery and relapse.
: This review aims to select and describe the most relevant findings to date. Selected clinical trials were found in PubMed using the following keywords ('methamphetamine') and ('addiction' OR 'withdrawal' OR 'treatment' OR 'pharmacotherapy'). Randomized placebo-controlled trials enrolling treatment-seeking METH-dependent subjects and inherent secondary analysis were included.
: Overall, end-of-treatment abstinence, reduced METH use or lower relapse rates were seen on METH dependent subgroups or attained significance only following
analysis, irrespective of the medication tested. For example, light and heavy METH users seem to respond differently to pharmacotherapy. This together with the heterogeneous nature of the METH dependent population strongly suggests that some drugs herein described (e.g. mirtazapine, methylphenidate) should be further tested in clinical trials focused on subgroups. Lastly, objective measures, such as urinalysis, are mandatory to include in clinical trials and early treatment response and/or medication compliance should be carefully monitored and considered as predictors of success/failure. |
---|---|
AbstractList | : Drug use related deaths are increasing and the lack of effective treatment for psychostimulants can be largely held responsible. Particularly, no pharmacotherapy is approved for methamphetamine (METH) use disorder despite decades of research. Only psychosocial interventions are clinically used, with limited long-term recovery and relapse.
: This review aims to select and describe the most relevant findings to date. Selected clinical trials were found in PubMed using the following keywords ('methamphetamine') and ('addiction' OR 'withdrawal' OR 'treatment' OR 'pharmacotherapy'). Randomized placebo-controlled trials enrolling treatment-seeking METH-dependent subjects and inherent secondary analysis were included.
: Overall, end-of-treatment abstinence, reduced METH use or lower relapse rates were seen on METH dependent subgroups or attained significance only following
analysis, irrespective of the medication tested. For example, light and heavy METH users seem to respond differently to pharmacotherapy. This together with the heterogeneous nature of the METH dependent population strongly suggests that some drugs herein described (e.g. mirtazapine, methylphenidate) should be further tested in clinical trials focused on subgroups. Lastly, objective measures, such as urinalysis, are mandatory to include in clinical trials and early treatment response and/or medication compliance should be carefully monitored and considered as predictors of success/failure. |
Author | Pereira, Frederico C Soares, Edna |
Author_xml | – sequence: 1 givenname: Edna surname: Soares fullname: Soares, Edna organization: Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal – sequence: 2 givenname: Frederico C surname: Pereira fullname: Pereira, Frederico C organization: Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31671001$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j1tLxDAUhIMo7kV_gpI_0HpOLyeNb7J4gwUF9XlJmtNtxV5I0gf_vQWVeRhmYAa-jTgdxoGFuEJIESq4wYLKRZRmgDpFqlArOBFrVEWRKCJaiU0InwAZ6LI4F6scSSEArsXba2t8b-oxtuzNxHPsahmiN5GPHQfZjF72HFvTTy1H03cDyzmwdF0YvWN_K5fKyWUtw2yPfpyncCHOGvMV-PLPt-Lj4f5995TsXx6fd3f7pM6JYqItlBqs0Q03FVpAptI5x5TXqlmCZYKsBARbgSsI89pWzuQLoyVrlMq24vr3d5ptz-4w-a43_vvwT5f9AAJ9VDo |
CitedBy_id | crossref_primary_10_1007_s10461_022_03929_6 crossref_primary_10_1016_j_neuint_2021_105069 crossref_primary_10_1016_j_neuro_2020_09_001 crossref_primary_10_1111_add_16610 crossref_primary_10_1016_j_drugalcdep_2022_109274 crossref_primary_10_1007_s00213_022_06252_z crossref_primary_10_1016_j_drugalcdep_2021_108572 crossref_primary_10_1016_j_cjca_2021_10_008 crossref_primary_10_1056_NEJMoa2020214 crossref_primary_10_1176_appi_ps_20220196 crossref_primary_10_1016_j_drugalcdep_2022_109537 crossref_primary_10_3389_fpsyt_2023_1208120 crossref_primary_10_1016_j_drugalcdep_2021_108904 crossref_primary_10_1016_j_bbr_2022_113876 crossref_primary_10_1111_adb_13205 crossref_primary_10_3390_vaccines10091508 crossref_primary_10_3389_fpsyt_2023_1147060 crossref_primary_10_1016_j_fct_2021_111970 crossref_primary_10_3390_ijms231710092 crossref_primary_10_1016_j_pharmthera_2021_107831 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1080/14656566.2019.1681970 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1744-7666 |
ExternalDocumentID | 31671001 |
Genre | Journal Article Review |
GroupedDBID | --- 00X 03L 0BK 0R~ 29G 4.4 53G 5GY AAMIU AAOUU AAPWH ABBAB ABEIZ ABJNI ABJYH ABLIJ ABLKL ABVAX ABXYU ACGFS ACIEZ ADCVX ADRBQ ADTOD AECIN AENEX AEOZL AGDLA AGMLL AIJEM AIRBT AIYSM AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU BABNJ BLEHA CAZVN CCCUG CGR CKQYL CS3 CUY CVF DASJU DAWQK DKSSO DU5 EBS ECM EIF EJD EMOBN F5P H13 HZ~ KRBQP KSSTO KUULJ KWAYT KYCEM LJTGL LSO M44 M4Z NPM O9- P2P RNANH TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TZHSB V1S ~1N |
ID | FETCH-LOGICAL-c366t-9b0590ba9fef81b01e65ddde63c7f1e6be6025010b80d4613cb8da3201b6ba772 |
IngestDate | Thu Jan 02 22:58:43 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 18 |
Keywords | clinical trials subgroups methamphetamine Drug use disorder pharmacotherapy |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c366t-9b0590ba9fef81b01e65ddde63c7f1e6be6025010b80d4613cb8da3201b6ba772 |
PMID | 31671001 |
ParticipantIDs | pubmed_primary_31671001 |
PublicationCentury | 2000 |
PublicationDate | 2019-12-12 |
PublicationDateYYYYMMDD | 2019-12-12 |
PublicationDate_xml | – month: 12 year: 2019 text: 2019-12-12 day: 12 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Expert opinion on pharmacotherapy |
PublicationTitleAlternate | Expert Opin Pharmacother |
PublicationYear | 2019 |
SSID | ssj0020954 |
Score | 2.3567805 |
SecondaryResourceType | review_article |
Snippet | : Drug use related deaths are increasing and the lack of effective treatment for psychostimulants can be largely held responsible. Particularly, no... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 2273 |
SubjectTerms | Amphetamine-Related Disorders - drug therapy Central Nervous System Stimulants - administration & dosage Central Nervous System Stimulants - adverse effects Humans Male Methamphetamine - adverse effects Methylphenidate - therapeutic use Randomized Controlled Trials as Topic |
Title | Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31671001 |
Volume | 20 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEF6qgngR32_Zg3ip0aTZbjfeRJQiKAUreFJ2NxvwYCwmPdRf78xu0qS14uMS0l2SlJ0v02-nM98QcqQj2RLtWHtRrKWHiuCejEzb49IY3olNEEqMQ97e8e4Du3lsPzYaT7WspWGuTvXHzLqS_1gVxsCuWCX7B8uObwoDcA72hSNYGI6_snGv0J2uFVE1s7wUf7AZhNghWoLFTC5fkVAOM4N_yljFTYwGwKDLoMyGylZ4ZBOxehRCzptYVGWJZdocTDxyHI-_f8M6JutY41RW_vbdvNhGRkCQUbUCYFeEZYtAQ2C7JBQpzsY5xw5jXoe7Liml92z5dZSIui9suSYlX5y0y2oMUKkNyCSm10WnAQdq4lqI1Aw3eLWWw2p91Ir6eXZKO7ucmiNz4EexLSrGcortOJBLVtZ0Cf9s5vdZIovlPab2HZZ_9FfIcrFxoBcOBaukYdI1clwgYHRC-xUGshN6THuVJvlondzPgAqtoEIBKnQKKhSgQkuonFMECoWr6RgoG-Th-qp_2fWKfhqeDjnPvUhhpbGSUWIS2K34geHtGH7eeKg7CXxQhiMjDnwl_JgBz9NKxDKE9VBcSdiGbZL59C0124QaLSTn-FaLhPmSCa61H4UxY0pEkrEdsuUW63ngRFOey2Xc_XZmjyxVsNsnCwm8peYAKF-uDq3lPgFDBVhJ |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacotherapeutic+strategies+for+methamphetamine+use+disorder%3A+mind+the+subgroups&rft.jtitle=Expert+opinion+on+pharmacotherapy&rft.au=Soares%2C+Edna&rft.au=Pereira%2C+Frederico+C&rft.date=2019-12-12&rft.eissn=1744-7666&rft.volume=20&rft.issue=18&rft.spage=2273&rft_id=info:doi/10.1080%2F14656566.2019.1681970&rft_id=info%3Apmid%2F31671001&rft_id=info%3Apmid%2F31671001&rft.externalDocID=31671001 |